| **Eligibility Term**                                                     | **Cancer Type** | **Category**        | **% of Trials (in category)** | **Inclusion/Exclusion** | **FHIR Resource**   | **Code (LOINC/SNOMED/ICD)**       | **Unstructured EMR Example**                                             |
| ------------------------------------------------------------------------ | --------------- | ------------------- | ----------------------------- | ----------------------- | ------------------- | --------------------------------- | ------------------------------------------------------------------------ |
| ECOG Performance Status ≤ 1 or 2                                         | Lung Cancer     | Clinical            | 100%                          | Inclusion               | Observation         | LOINC: 89243-0                    | ECOG score was 1 on baseline report                                      |
| Histologically or cytologically confirmed NSCLC                          | Lung Cancer     | Diagnosis           | 100%                          | Inclusion               | Condition           | SNOMED: 254637007                 | Biopsy confirmed adenocarcinoma of the lung                              |
| Stage IV NSCLC (squamous or non-squamous)                                | Lung Cancer     | Diagnosis           | 93.3%                         | Inclusion               | Condition           | ICD-10: C34.x                     | Diagnosed with Stage IV NSCLC via PET-CT                                 |
| Measurable disease per RECIST 1.1                                        | Lung Cancer     | Imaging             | 86.7%                         | Inclusion               | Observation         | SNOMED: 371861004                 | CT scan revealed lesion measurable under RECIST                          |
| No prior systemic therapy for advanced NSCLC                             | Lung Cancer     | Treatment History   | 80%                           | Inclusion               | Procedure           | SNOMED: 410942007                 | No record of systemic chemotherapy                                       |
| PD-L1 testing available                                                  | Lung Cancer     | Pathology           | 60%                           | Inclusion               | Observation         | LOINC: 85337-4                    | PD-L1 IHC showed 65% expression                                          |
| EGFR-sensitizing mutation exclusion                                      | Lung Cancer     | Genetic             | 46.7%                         | Exclusion               | Observation         | LOINC: 92822-6                    | EGFR L858R mutation detected in genomic report                           |
| Untreated CNS metastases                                                 | Lung Cancer     | Imaging             | 73.3%                         | Exclusion               | Condition           | ICD-10: C79.31                    | Brain MRI showed active metastatic lesion                                |
| ALK translocation exclusion                                              | Lung Cancer     | Genetic             | 33.3%                         | Exclusion               | Observation         | LOINC: 81248-5                    | ALK positive via FISH analysis                                           |
| History of autoimmune disease                                            | Lung Cancer     | Medical History     | 66.7%                         | Exclusion               | Condition           | SNOMED: 64572001                  | Past medical history includes lupus                                      |
| Positive HIV test                                                        | Lung Cancer     | Infection           | 60%                           | Exclusion               | Observation         | LOINC: 56888-1                    | HIV status: Positive in serology report                                  |
| Active Hepatitis B or C                                                  | Lung Cancer     | Infection           | 60%                           | Exclusion               | Observation         | LOINC: 5195-3 / 20416-4           | Hepatitis B surface antigen: positive                                    |
| Life expectancy ≥ 3 months                                               | Lung Cancer     | Clinical            | 46.7%                         | Inclusion               | Observation         | SNOMED: 397709008                 | Oncologist estimates >3 month survival                                   |
| Prior treatment with PD-1/PD-L1 inhibitors                               | Lung Cancer     | Treatment History   | 53.3%                         | Exclusion               | Procedure           | SNOMED: 428341000124102           | Received nivolumab in past                                               |
| Adequate organ function                                                  | Lung Cancer     | Lab                 | 93.3%                         | Inclusion               | Observation         | LOINC Panel                       | Creatinine, AST/ALT, WBC within limits                                   |
| No prior chemotherapy for metastatic NSCLC                               | Lung Cancer     | Treatment History   | 73.3%                         | Inclusion               | Procedure           | SNOMED: 371533000                 | No chemotherapy recorded post-stage IV diagnosis                         |
| Negative pregnancy test (females)                                        | Lung Cancer     | Reproductive        | 53.3%                         | Inclusion               | Observation         | LOINC: 19080-1                    | Urine HCG test: Negative                                                 |
| Use of contraception during and after study                              | Lung Cancer     | Reproductive        | 66.7%                         | Inclusion               | Observation         | SNOMED: 243796009                 | Advised to continue contraceptives for 180 days                          |
| No prior immunotherapy (e.g., checkpoint inhibitors)                     | Lung Cancer     | Treatment History   | 46.7%                         | Inclusion               | Procedure           | SNOMED: 18286008                  | Immunotherapy history: none                                              |
| Active autoimmune condition needing systemic therapy                     | Lung Cancer     | Medical History     | 46.7%                         | Exclusion               | Condition           | SNOMED: 69896004                  | Patient has Crohn’s disease on steroids                                  |
| ILD or pneumonitis history                                               | Lung Cancer     | Respiratory         | 40%                           | Exclusion               | Condition           | SNOMED: 67782005                  | HRCT shows fibrosis suggestive of ILD                                    |
| Recent major surgery (<4 weeks)                                          | Lung Cancer     | Surgery             | 33.3%                         | Exclusion               | Procedure           | SNOMED: 387713003                 | Surgery completed 3 weeks ago                                            |
| Active infection requiring IV therapy                                    | Lung Cancer     | Infection           | 26.7%                         | Exclusion               | Condition           | SNOMED: 87628006                  | Admitted for IV antibiotics for pneumonia                                |
| EGFR Exon 19 deletion or L858R required                                  | Lung Cancer     | Genetic             | 26.7%                         | Inclusion               | Observation         | LOINC: 85183-2                    | EGFR exon 19 deletion detected                                           |
| Prior radiation >30 Gy to lungs                                          | Lung Cancer     | Treatment History   | 20%                           | Exclusion               | Procedure           | SNOMED: 122471000119102           | Prior thoracic RT of 35 Gy                                               |
| No active second malignancy (last 5 years)                               | Lung Cancer     | Diagnosis           | 53.3%                         | Exclusion               | Condition           | SNOMED: 399981008                 | Prior cancer history: prostate (cured)                                   |
| No live vaccines 30 days prior                                           | Lung Cancer     | Immunization        | 26.7%                         | Exclusion               | Procedure           | SNOMED: 33879002                  | Received MMR vaccine 15 days before screening                            |
| QTc ≤ 470 ms                                                             | Lung Cancer     | Cardiac             | 26.7%                         | Inclusion               | Observation         | LOINC: 8649-2                     | ECG shows QTc of 460 ms                                                  |
| Symptomatic or unstable CNS metastases                                   | Lung Cancer     | Neurologic          | 33.3%                         | Exclusion               | Condition           | SNOMED: 312912007                 | Brain MRI: active lesion with edema                                      |
| No investigational drug in last 4 weeks                                  | Lung Cancer     | Treatment History   | 40%                           | Exclusion               | Procedure           | SNOMED: 429457009                 | Enrolled in drug trial 2 weeks prior                                     |
| No prior ALK-TKI therapy                                                 | Lung Cancer     | Treatment History   | 20%                           | Exclusion               | Procedure           | SNOMED: 432137009                 | Never received crizotinib                                                |
| RET fusion-positive tumor                                                | Lung Cancer     | Genetic             | 6.7%                          | Inclusion               | Observation         | LOINC: 81286-5                    | RET rearrangement detected in NGS report                                 |
| Measurable tumor per imaging                                             | Lung Cancer     | Imaging             | 86.7%                         | Inclusion               | Observation         | SNOMED: 36971009                  | CT: Lesion >10 mm in RUL                                                 |
| Recovery from prior therapy/surgery                                      | Lung Cancer     | Treatment History   | 40%                           | Inclusion               | Procedure           | SNOMED: 304527002                 | Recovered from lobectomy 3 weeks prior                                   |
| Stable treated CNS metastases                                            | Lung Cancer     | Imaging             | 33.3%                         | Inclusion               | Condition           | SNOMED: 422504002                 | Brain metastases treated and resolved                                    |
| Prior hypersensitivity to monoclonal antibodies                          | Lung Cancer     | Allergy             | 33.3%                         | Exclusion               | Condition           | SNOMED: 294967001                 | Documented reaction to bevacizumab                                       |
| Chronic systemic steroid use                                             | Lung Cancer     | Medication          | 33.3%                         | Exclusion               | MedicationStatement | RxNorm: 8610                      | Prednisolone 10 mg daily for 2 months                                    |
| Squamous histology exclusion (some trials)                               | Lung Cancer     | Pathology           | 20%                           | Exclusion               | Observation         | SNOMED: 399919001                 | Histology: squamous cell carcinoma                                       |
| Inadequate renal function                                                | Lung Cancer     | Lab                 | 26.7%                         | Exclusion               | Observation         | LOINC: 2160-0                     | Creatinine clearance < 30 ml/min                                         |
| Hepatitis B surface antigen positive                                     | Lung Cancer     | Infection           | 40%                           | Exclusion               | Observation         | LOINC: 5195-3                     | HBsAg test: reactive                                                     |
| Tumor tissue availability for testing                                    | Lung Cancer     | Pathology           | 53.3%                         | Inclusion               | Specimen            | SNOMED: 119294006                 | FFPE tumor block submitted for analysis                                  |
| Use of strong CYP3A4 inducers                                            | Lung Cancer     | Medication          | 26.7%                         | Exclusion               | MedicationStatement | RxNorm: 1049626                   | Taking rifampin for TB                                                   |
| Severe cardiovascular disease                                            | Lung Cancer     | Medical History     | 33.3%                         | Exclusion               | Condition           | SNOMED: 49601007                  | Congestive heart failure (NYHA Class III)                                |
| Organ transplant history                                                 | Lung Cancer     | Medical History     | 13.3%                         | Exclusion               | Procedure           | SNOMED: 67166004                  | Kidney transplant in 2012                                                |
| Pregnant or breastfeeding                                                | Lung Cancer     | Reproductive        | 60%                           | Exclusion               | Observation         | SNOMED: 77386006                  | Pregnancy confirmed via urine HCG                                        |
| Non-childbearing potential (female)                                      | Lung Cancer     | Reproductive        | 26.7%                         | Inclusion               | Observation         | SNOMED: 434481000124105           | Post-menopausal, not at risk of pregnancy                                |
| Inadequate hematologic function                                          | Lung Cancer     | Lab                 | 46.7%                         | Exclusion               | Observation         | LOINC Panel                       | WBC < 3.0, Hb < 9.0                                                      |
| Major surgery within 3–4 weeks                                           | Lung Cancer     | Surgery             | 46.7%                         | Exclusion               | Procedure           | SNOMED: 387713003                 | Lobectomy performed 2 weeks ago                                          |
| Need for concurrent anticancer therapy                                   | Lung Cancer     | Treatment History   | 26.7%                         | Exclusion               | Procedure           | SNOMED: 385763009                 | Required radiation during trial period                                   |
| Hypersensitivity to platinum compounds                                   | Lung Cancer     | Allergy             | 13.3%                         | Exclusion               | Condition           | SNOMED: 294968006                 | Allergic to carboplatin                                                  |
| Interstitial Lung Disease (ILD) history                                  | Lung Cancer     | Pulmonary           | 46.7%                         | Exclusion               | Condition           | SNOMED: 233604007                 | ILD noted in prior CT scan and medical records                           |
| Radiation pneumonitis history                                            | Lung Cancer     | Pulmonary           | 26.7%                         | Exclusion               | Condition           | SNOMED: 199006007                 | Fibrosis from prior chest radiation present                              |
| No EGFR or ALK mutation                                                  | Lung Cancer     | Genetic             | 26.7%                         | Exclusion               | Observation         | LOINC: 69548-6                    | EGFR mutation: negative                                                  |
| PD-L1 status known (IHC)                                                 | Lung Cancer     | Biomarker           | 40%                           | Inclusion               | Observation         | LOINC: 85337-4                    | Tumor PD-L1 TPS: 50%                                                     |
| Active Hepatitis C infection                                             | Lung Cancer     | Infection           | 40%                           | Exclusion               | Observation         | LOINC: 13955-0                    | HCV RNA positive                                                         |
| Prior docetaxel therapy                                                  | Lung Cancer     | Treatment History   | 13.3%                         | Exclusion               | Procedure           | SNOMED: 440376006                 | Treated with docetaxel in prior regimen                                  |
| Recent systemic infection (last 4 weeks)                                 | Lung Cancer     | Infection           | 26.7%                         | Exclusion               | Condition           | SNOMED: 87628006                  | Hospitalized for sepsis 3 weeks ago                                      |
| Refractory nausea/vomiting                                               | Lung Cancer     | GI                  | 13.3%                         | Exclusion               | Condition           | SNOMED: 28944009                  | Nausea uncontrolled by medication                                        |
| Impaired drug absorption (GI disorders)                                  | Lung Cancer     | GI                  | 20%                           | Exclusion               | Condition           | SNOMED: 7163003                   | Crohn’s disease affecting absorption                                     |
| Severe liver impairment                                                  | Lung Cancer     | Lab                 | 13.3%                         | Exclusion               | Observation         | LOINC Panel                       | ALT/AST > 3× ULN                                                         |
| Blood transfusion requirement                                            | Lung Cancer     | Clinical            | 6.7%                          | Exclusion               | Procedure           | SNOMED: 46705006                  | Receiving packed red cells weekly                                        |
| Unable to swallow oral medications                                       | Lung Cancer     | Clinical            | 13.3%                         | Exclusion               | Observation         | SNOMED: 162057007                 | Patient has dysphagia from esophageal mass                               |
| Performance Status WHO 0–1                                               | Lung Cancer     | Clinical            | 26.7%                         | Inclusion               | Observation         | SNOMED: 443761000124104           | WHO PS recorded as 0                                                     |
| Tumor PD-L1 ≥ 50%                                                        | Lung Cancer     | Biomarker           | 13.3%                         | Inclusion               | Observation         | LOINC: 85337-4                    | IHC shows TPS score of 70%                                               |
| Prior checkpoint inhibitor use                                           | Lung Cancer     | Treatment History   | 26.7%                         | Exclusion               | Procedure           | SNOMED: 433144002                 | Received nivolumab in past 6 months                                      |
| Anti-PD-1/PD-L1/PD-L2 exposure                                           | Lung Cancer     | Treatment History   | 33.3%                         | Exclusion               | Procedure           | SNOMED: 433144002                 | History of pembrolizumab use                                             |
| Asymptomatic CNS metastases allowed                                      | Lung Cancer     | Neurologic          | 13.3%                         | Inclusion               | Condition           | SNOMED: 312912007                 | Brain lesion stable on follow-up MRI                                     |
| No symptomatic bradycardia                                               | Lung Cancer     | Cardiac             | 6.7%                          | Exclusion               | Observation         | LOINC: 8867-4                     | Heart rate: 40 bpm, dizziness reported                                   |
| Prior platinum-based chemotherapy                                        | Lung Cancer     | Treatment History   | 33.3%                         | Inclusion               | Procedure           | SNOMED: 4471000126108             | Treated with cisplatin + pemetrexed                                      |
| Resected Stage IB–IIIA NSCLC                                             | Lung Cancer     | Diagnosis           | 13.3%                         | Inclusion               | Condition           | SNOMED: 254637007                 | Surgical pathology: Stage IIA NSCLC                                      |
| No unresolved toxicity > Grade 1                                         | Lung Cancer     | Clinical            | 13.3%                         | Exclusion               | Observation         | SNOMED: 2741000046100             | Grade 2 neuropathy persisted post-therapy                                |
| Immunosuppressive therapy usage                                          | Lung Cancer     | Medication          | 20%                           | Exclusion               | MedicationStatement | RxNorm: 8665                      | Long-term prednisone use noted                                           |
| Prior CD137 agonist exposure                                             | Lung Cancer     | Treatment History   | 13.3%                         | Exclusion               | Procedure           | SNOMED: 41291007                  | Received CD137 antibody in phase I trial                                 |
| Current or recent drug/alcohol abuse                                     | Lung Cancer     | Behavioral          | 26.7%                         | Exclusion               | Condition           | SNOMED: 191816009                 | Positive urine screen for cannabis                                       |
| Inability to comply with protocol                                        | Lung Cancer     | Clinical            | 33.3%                         | Exclusion               | Observation         | SNOMED: 27624003                  | Cognitive impairment noted, poor compliance                              |
| Major surgery within 3–4 weeks                                           | Lung Cancer     | Treatment History   | 60%                           | Exclusion               | Procedure           | SNOMED: 387713003                 | Thoracotomy performed 2 weeks prior                                      |
| QTc >470 ms or ECG abnormality                                           | Lung Cancer     | Cardiac             | 40%                           | Exclusion               | Observation         | LOINC: 77606-2                    | QTc interval measured 480 ms                                             |
| Pregnancy or lactation                                                   | Lung Cancer     | Reproductive        | 100%                          | Exclusion               | Observation         | LOINC: 19080-1                    | Positive serum pregnancy test                                            |
| Use of strong CYP3A inducers/inhibitors                                  | Lung Cancer     | Medication          | 26.7%                         | Exclusion               | MedicationStatement | RxNorm Group                      | Taking ketoconazole regularly                                            |
| No live vaccine within 30 days                                           | Lung Cancer     | Immunization        | 20%                           | Exclusion               | Immunization        | CVX: 01 (MMR)                     | Received yellow fever vaccine 10 days prior                              |
| Participation in another trial                                           | Lung Cancer     | Treatment History   | 40%                           | Exclusion               | ResearchStudy       | SNOMED: 308292007                 | On an investigational protocol for melanoma                              |
| Grade ≥2 neuropathy                                                      | Lung Cancer     | Neurologic          | 13.3%                         | Exclusion               | Observation         | SNOMED: 230686007                 | Complains of burning foot pain and numbness                              |
| Prior hypersensitivity to study drugs                                    | Lung Cancer     | Allergy             | 26.7%                         | Exclusion               | AllergyIntolerance  | SNOMED: 294967001                 | History of rash with paclitaxel                                          |
| Prior EGFR/ALK TKI treatment                                             | Lung Cancer     | Treatment History   | 20%                           | Exclusion               | MedicationStatement | RxNorm: 398181 (erlotinib)        | Was treated with erlotinib 1 year ago                                    |
| Tumor sample available for biomarker testing                             | Lung Cancer     | Biomarker           | 33.3%                         | Inclusion               | Specimen            | SNOMED: 119376003                 | FFPE tumor block sent to central lab                                     |
| Stable CNS metastases allowed                                            | Lung Cancer     | Neurologic          | 20%                           | Inclusion               | Condition           | SNOMED: 312912007                 | Brain mets treated 4 weeks ago, stable MRI                               |
| Not eligible if squamous histology                                       | Lung Cancer     | Diagnosis           | 20%                           | Exclusion               | Condition           | SNOMED: 254637007                 | Biopsy shows squamous cell carcinoma                                     |
| Tumor EGFR activating mutation (Ex19del or L858R)                        | Lung Cancer     | Genetic             | 33.3%                         | Inclusion               | Observation         | LOINC: 48018-6                    | EGFR exon 19 deletion present                                            |
| Use of systemic corticosteroids                                          | Lung Cancer     | Medication          | 33.3%                         | Exclusion               | MedicationStatement | RxNorm: 1049220                   | Prednisone 20mg daily for arthritis                                      |
| No prior systemic therapy for advanced NSCLC                             | Lung Cancer     | Treatment History   | 53.3%                         | Inclusion               | Procedure           | SNOMED: 4471000126108             | No chemo/immunotherapy since diagnosis                                   |
| Significant comorbid illness interfering with study                      | Lung Cancer     | Clinical            | 26.7%                         | Exclusion               | Condition           | SNOMED: 162607003                 | NYHA Class III CHF noted                                                 |
| Prior radiation >30 Gy to lungs                                          | Lung Cancer     | Treatment History   | 40%                           | Exclusion               | Procedure           | SNOMED: 108290001                 | Prior RT: 35 Gy to left upper lobe                                       |
| Pemetrexed ineligibility (e.g., squamous histology)                      | Lung Cancer     | Treatment History   | 13.3%                         | Exclusion               | Procedure           | SNOMED: 428191000124100           | Cannot receive pemetrexed (squamous histology)                           |
| CNS metastases or leptomeningeal disease                                 | Lung Cancer     | Neurologic          | 33.3%                         | Exclusion               | Condition           | SNOMED: 312912007                 | Brain MRI showed leptomeningeal enhancement                              |
| Prior allogeneic transplant                                              | Lung Cancer     | Treatment History   | 13.3%                         | Exclusion               | Procedure           | SNOMED: 430193006                 | Allogeneic bone marrow transplant 5 years ago                            |
| Immune checkpoint inhibitors not previously received                     | Lung Cancer     | Treatment History   | 26.7%                         | Inclusion               | Procedure           | SNOMED: 433144002                 | Patient is immunotherapy-naive                                           |
| Female/male contraception commitment                                     | Lung Cancer     | Reproductive        | 80%                           | Inclusion               | Observation         | SNOMED: 364703007                 | Using IUD and barrier method                                             |
| Prior CTLA-4 inhibitor use                                               | Lung Cancer     | Treatment History   | 13.3%                         | Exclusion               | MedicationStatement | SNOMED: 372729009                 | Previously treated with ipilimumab                                       |
| Symptomatic bradycardia/QT prolongation                                  | Lung Cancer     | Cardiac             | 13.3%                         | Exclusion               | Observation         | LOINC: 8867-4                     | HR: 42 bpm with dizziness noted                                          |
| Life expectancy ≥12 weeks                                                | Lung Cancer     | Clinical            | 33.3%                         | Inclusion               | Observation         | SNOMED: 75273003                  | Oncologist estimates survival >3 months                                  |
| Histologically confirmed adenocarcinoma of the breast                    | Breast Cancer   | Diagnosis           | 100%                          | Inclusion               | Condition           | ICD-10: C50                       | Biopsy confirmed invasive adenocarcinoma of the left breast              |
| ER and/or PR positive tumor                                              | Breast Cancer   | Pathology           | 46%                           | Inclusion               | Observation         | LOINC: 85337-4 (ER); 85339-0 (PR) | Estrogen receptor positive, PR borderline positive on IHC                |
| HER2-negative tumor by FISH or IHC                                       | Breast Cancer   | Pathology           | 38%                           | Inclusion               | Observation         | LOINC: 48676-1                    | HER2 score was 1+ by IHC, FISH negative                                  |
| HER2-positive tumor confirmed by IHC or FISH                             | Breast Cancer   | Pathology           | 46%                           | Inclusion               | Observation         | LOINC: 48676-1                    | HER2 score was 3+ by IHC                                                 |
| Triple-negative breast cancer (ER-, PR-, HER2-)                          | Breast Cancer   | Pathology           | 23%                           | Inclusion               | Observation         | SNOMED: 76751001                  | Pathology report confirms TNBC phenotype                                 |
| ECOG Performance Status 0 or 1                                           | Breast Cancer   | Clinical            | 61%                           | Inclusion               | Observation         | LOINC: 89243-0                    | ECOG PS was 1 at baseline assessment                                     |
| No prior invasive breast cancer                                          | Breast Cancer   | Treatment History   | 38%                           | Exclusion               | Condition           | ICD-10: C50                       | No documented history of contralateral or ipsilateral invasive breast CA |
| LVEF ≥ 50%                                                               | Breast Cancer   | Clinical            | 31%                           | Inclusion               | Observation         | LOINC: 33878-0                    | Baseline LVEF on MUGA scan measured 55%                                  |
| CNS metastases present                                                   | Breast Cancer   | Imaging/Diagnosis   | 23%                           | Exclusion               | Condition           | ICD-10: C79.31                    | MRI brain shows metastatic lesion in the frontal lobe                    |
| Chronic obstructive pulmonary disease requiring treatment                | Breast Cancer   | Comorbidity         | 8%                            | Exclusion               | Condition           | ICD-10: J44.9                     | COPD with ongoing bronchodilator therapy                                 |
| Documented BRCA1 or BRCA2 germline mutation                              | Breast Cancer   | Genetic             | 23%                           | Inclusion               | Observation         | LOINC: 81241-3                    | Patient tested positive for germline BRCA1 mutation via Myriad Genetics  |
| Measurable disease per RECIST v1.1                                       | Breast Cancer   | Imaging             | 46%                           | Inclusion               | Observation         | SNOMED: 386053000                 | CT scan shows measurable target lesion in liver, 20mm in diameter        |
| Life expectancy ≥ 12 weeks                                               | Breast Cancer   | Clinical            | 15%                           | Inclusion               | Observation         | SNOMED: 75283002                  | Oncologist estimates patient's life expectancy is at least 3 months      |
| Adequate hematologic, renal, and hepatic function                        | Breast Cancer   | Lab                 | 77%                           | Inclusion               | Observation         | Multiple LOINC codes              | CBC, LFTs, and creatinine levels all within normal range                 |
| Platelet count ≥ 100,000/mm³                                             | Breast Cancer   | Lab                 | 15%                           | Inclusion               | Observation         | LOINC: 26515-7                    | Platelet count is 145,000/mm³ on recent CBC                              |
| Serum creatinine ≤ 1.5 mg/dL                                             | Breast Cancer   | Lab                 | 15%                           | Inclusion               | Observation         | LOINC: 2160-0                     | Creatinine measured 1.2 mg/dL at baseline                                |
| AST ≤ 3× upper institutional limit                                       | Breast Cancer   | Lab                 | 15%                           | Inclusion               | Observation         | LOINC: 1920-8                     | AST was 84 IU/L, within 3× ULN of 40 IU/L                                |
| No prior chemotherapy for metastatic disease                             | Breast Cancer   | Treatment History   | 31%                           | Exclusion               | Procedure           | SNOMED: 385763009                 | Patient has not received chemotherapy since metastatic diagnosis         |
| No prior treatment with PARP inhibitors                                  | Breast Cancer   | Treatment History   | 15%                           | Exclusion               | Procedure           | SNOMED: 473942006                 | No prior exposure to olaparib, niraparib, or talazoparib                 |
| Pregnant or breastfeeding women excluded                                 | Breast Cancer   | Reproductive        | 85%                           | Exclusion               | Condition           | ICD-10: Z33.1, Z39.1              | Pregnancy test positive; patient not eligible                            |
| History of congestive heart failure or cardiac arrhythmia                | Breast Cancer   | Comorbidity         | 31%                           | Exclusion               | Condition           | ICD-10: I50, I49                  | History of CHF with reduced ejection fraction; also treated for AFib     |
| Uncontrolled hypertension                                                | Breast Cancer   | Comorbidity         | 15%                           | Exclusion               | Condition           | ICD-10: I10                       | Blood pressure consistently above 160/100 despite medication             |
| Myocardial infarction within 6–12 months                                 | Breast Cancer   | Comorbidity         | 15%                           | Exclusion               | Condition           | ICD-10: I21                       | Patient had STEMI 8 months ago and underwent PCI                         |
| CNS metastases or leptomeningeal disease                                 | Breast Cancer   | Imaging/Diagnosis   | 38%                           | Exclusion               | Condition           | ICD-10: C79.31, G96.0             | MRI shows enhancing leptomeningeal spread and multiple brain metastases  |
| Active autoimmune disease requiring systemic treatment                   | Breast Cancer   | Comorbidity         | 23%                           | Exclusion               | Condition           | SNOMED: 370388006                 | Patient on prednisone 10mg daily for lupus                               |
| Peripheral neuropathy ≥ Grade 2                                          | Breast Cancer   | Clinical            | 23%                           | Exclusion               | Observation         | SNOMED: 302226006                 | Complains of numbness and tingling, grade 2 neuropathy per CTCAE         |
| Chronic liver disease or cirrhosis                                       | Breast Cancer   | Comorbidity         | 15%                           | Exclusion               | Condition           | ICD-10: K74.60                    | Diagnosed cirrhosis secondary to hepatitis C                             |
| History of tuberculosis (active or prior)                                | Breast Cancer   | Comorbidity         | 8%                            | Exclusion               | Condition           | ICD-10: A15–A19                   | Past medical history includes treated pulmonary TB                       |
| Interstitial lung disease or pneumonitis                                 | Breast Cancer   | Comorbidity         | 15%                           | Exclusion               | Condition           | ICD-10: J84.10, J84.89            | High-resolution CT shows signs of ILD                                    |
| Psychiatric or substance abuse disorder affecting compliance             | Breast Cancer   | Comorbidity         | 38%                           | Exclusion               | Condition           | ICD-10: F10–F19, F30–F39          | Patient has bipolar disorder and history of noncompliance with treatment |
| Prior use of tamoxifen or other SERMs >1 year before diagnosis           | Breast Cancer   | Treatment History   | 15%                           | Exclusion               | MedicationStatement | SNOMED: 372729009                 | Patient has taken tamoxifen for 2 years prior to diagnosis               |
| Endocrine therapy for >8 months after diagnosis                          | Breast Cancer   | Treatment History   | 8%                            | Exclusion               | MedicationStatement | SNOMED: 428731000124101           | Started on letrozole 10 months ago, still on treatment                   |
| Prior bilateral oophorectomy or ovarian radiation                        | Breast Cancer   | Surgical History    | 15%                           | Exclusion               | Procedure           | SNOMED: 118698009                 | Surgical history includes bilateral oophorectomy 3 years ago             |
| Use of GnRH analogues before randomization                               | Breast Cancer   | Treatment History   | 8%                            | Exclusion               | MedicationStatement | SNOMED: 372729005                 | Patient was treated with goserelin 2 months before enrollment            |
| Current use of prohibited medications (e.g., CYP3A4 inducers/inhibitors) | Breast Cancer   | Medication          | 31%                           | Exclusion               | MedicationStatement | SNOMED: 428651000124104           | Patient is currently taking ketoconazole, a strong CYP3A4 inhibitor      |
| Use of herbal medications or QT-prolonging drugs                         | Breast Cancer   | Medication          | 23%                           | Exclusion               | MedicationStatement | SNOMED: 428651000124104           | St. John’s Wort noted in medication history                              |
| Postmenopausal women only                                                | Breast Cancer   | Reproductive        | 23%                           | Inclusion               | Observation         | SNOMED: 289903006                 | FSH and estradiol consistent with postmenopausal status                  |
| Premenopausal estradiol in normal range                                  | Breast Cancer   | Reproductive        | 15%                           | Inclusion               | Observation         | LOINC: 21189-6                    | E2 level was 120 pg/mL confirming premenopausal status                   |
| Use of effective nonhormonal contraception                               | Breast Cancer   | Reproductive        | 61%                           | Inclusion               | Observation         | SNOMED: 169909004                 | Patient uses copper IUD for contraception                                |
| Pregnancy test required within 2 weeks of registration                   | Breast Cancer   | Reproductive        | 46%                           | Inclusion               | Observation         | LOINC: 19080-1                    | Serum beta-hCG was negative 5 days prior to enrollment                   |
| No participation in another investigational trial within 28 days         | Breast Cancer   | Trial Participation | 38%                           | Exclusion               | ResearchStudy       | SNOMED: 409063005                 | Patient completed investigational therapy 35 days ago                    |
| No active or untreated second malignancy within 5 years                  | Breast Cancer   | Comorbidity         | 54%                           | Exclusion               | Condition           | ICD-10: C80.1                     | Diagnosed with Stage I colon cancer 3 years ago, now in remission        |
| Biopsy-confirmed locally advanced or metastatic disease                  | Breast Cancer   | Diagnosis           | 69%                           | Inclusion               | Condition           | ICD-10: C50 + staging codes       | Core biopsy confirms metastatic adenocarcinoma consistent with breast CA |
| Tumor tissue available for biomarker testing                             | Breast Cancer   | Pathology           | 38%                           | Inclusion               | Specimen            | SNOMED: 258241000                 | Paraffin blocks submitted for central PD-L1 testing                      |
| Adequate surgical margins post-resection                                 | Breast Cancer   | Surgical History    | 31%                           | Inclusion               | Procedure           | SNOMED: 387713003                 | Final pathology shows margins negative by >1 mm                          |
| No gross residual disease after surgery                                  | Breast Cancer   | Surgical History    | 15%                           | Inclusion               | Condition           | SNOMED: 118245000                 | Post-op imaging shows no residual tumor in surgical bed                  |
| Recurrent or metastatic disease not amenable to curative resection       | Breast Cancer   | Diagnosis           | 23%                           | Inclusion               | Condition           | ICD-10: C79 + Z85.3               | Recurrent disease infiltrating chest wall, not surgically resectable     |
| Prior breast surgery completed                                           | Breast Cancer   | Surgical History    | 69%                           | Inclusion               | Procedure           | SNOMED: 274441001                 | Patient underwent modified radical mastectomy 2 months ago               |
| Negative axillary lymph nodes                                            | Breast Cancer   | Diagnosis           | 15%                           | Inclusion               | Observation         | SNOMED: 43339004                  | Axillary node biopsy shows no malignant cells                            |
| Tumor size 1.1–5.0 cm or 5mm–1cm with poor histologic features           | Breast Cancer   | Pathology           | 15%                           | Inclusion               | Observation         | SNOMED: 254837009                 | Tumor size 0.8 cm, poorly differentiated, lymphovascular invasion noted  |
| Histologically confirmed Stage III or IV melanoma                        | Skin Cancer     | Diagnosis           | 10%                           | Inclusion               | Condition           | ICD-10: C43                       | Stage III melanoma confirmed via biopsy                                  |
| No prior systemic anti-cancer therapy                                    | Skin Cancer     | Treatment           | 10%                           | Inclusion               | Procedure           | SNOMED: 410942007                 | No prior systemic treatment documented                                   |
| Active autoimmune disease                                                | Skin Cancer     | Autoimmune          | 10%                           | Exclusion               | Condition           | SNOMED: 85828009                  | Patient has active lupus                                                 |
| Measurable disease per RECIST                                            | Skin Cancer     | Imaging             | 50%                           | Inclusion               | Observation         | SNOMED: 115727004                 | CT showed measurable lesion per RECIST criteria                          |
| Exclusion of ocular melanoma                                             | Skin Cancer     | Diagnosis           | 60%                           | Exclusion               | Condition           | ICD-10: C69.9                     | Diagnosis confirmed as ocular melanoma                                   |
| Untreated CNS metastases                                                 | Skin Cancer     | Neurological        | 50%                           | Exclusion               | Condition           | SNOMED: 127013003                 | Brain MRI showed untreated metastases                                    |
| Pregnancy or breastfeeding                                               | Skin Cancer     | Reproductive        | 60%                           | Exclusion               | Observation         | SNOMED: 289908002                 | Patient is currently pregnant                                            |
| Use of systemic corticosteroids                                          | Skin Cancer     | Treatment           | 40%                           | Exclusion               | Procedure           | SNOMED: 410942007                 | Patient on prednisone >10mg/day                                          |
| BRAF V600 mutation positive                                              | Skin Cancer     | Genetic             | 50%                           | Inclusion               | Observation         | LOINC: 73804-9                    | Tumor positive for BRAF V600E mutation                                   |
| Active autoimmune disease                                                | Skin Cancer     | Autoimmune          | 50%                           | Exclusion               | Condition           | SNOMED: 64572001                  | Diagnosed with active lupus                                              |
| Prior systemic anti-cancer therapy                                       | Skin Cancer     | Treatment           | 40%                           | Exclusion               | Procedure           | SNOMED: 385763009                 | Previously treated with checkpoint inhibitor                             |
| Active infection requiring systemic therapy                              | Skin Cancer     | Infection           | 30%                           | Exclusion               | Observation         | LOINC: 11488-4                    | IV antibiotics started for active pneumonia                              |
| Ocular or uveal melanoma                                                 | Skin Cancer     | Diagnosis           | 40%                           | Exclusion               | Condition           | ICD-10: C69.3                     | Diagnosed with uveal melanoma                                            |
| Measurable disease per RECIST v1.1                                       | Skin Cancer     | Imaging             | 40%                           | Inclusion               | Observation         | SNOMED: 1153571001                | CT scan shows 2.5 cm measurable mass                                     |
| Untreated or unstable CNS metastases                                     | Skin Cancer     | Neurological        | 40%                           | Exclusion               | Condition           | SNOMED: 128613002                 | MRI revealed untreated brain metastasis                                  |
| Pregnant, breastfeeding, or planning pregnancy                           | Skin Cancer     | Reproductive        | 60%                           | Exclusion               | Observation         | SNOMED: 77386006                  | Patient currently breastfeeding                                          |
| Use of systemic corticosteroids or immunosuppressants                    | Skin Cancer     | Treatment           | 50%                           | Exclusion               | Procedure           | SNOMED: 428191000000100           | On prednisone 20 mg for past 10 days                                     |
| ECOG performance status 0 or 1                                           | Skin Cancer     | Clinical            | 90%                           | Inclusion               | Observation         | LOINC: 89243-0                    | ECOG performance status documented as 1                                  |
| History of autoimmune disease                                            | Skin Cancer     | Autoimmune          | 40%                           | Exclusion               | Condition           | SNOMED: 64572001                  | Patient has history of rheumatoid arthritis                              |
| HIV, active hepatitis B or C                                             | Skin Cancer     | Infection           | 40%                           | Exclusion               | Observation         | LOINC: 29771-3, 20416-4           | HIV test returned positive                                               |
| Use of live vaccines within 30 days prior to treatment                   | Skin Cancer     | Immunization        | 30%                           | Exclusion               | Procedure           | SNOMED: 33879002                  | Patient received yellow fever vaccine 3 weeks ago                        |
| Retinal disorders (e.g., RVO, CSR, macular degeneration)                 | Skin Cancer     | Ophthalmologic      | 20%                           | Exclusion               | Condition           | SNOMED: 44189001                  | Fundoscopy shows signs of central serous retinopathy                     |
| Ocular or uveal melanoma excluded                                        | Skin Cancer     | Diagnosis           | 50%                           | Exclusion               | Condition           | SNOMED: 9400001                   | Diagnosis indicates ocular melanoma                                      |
| No prior systemic therapy for advanced melanoma                          | Skin Cancer     | Treatment           | 60%                           | Inclusion               | Procedure           | SNOMED: 386053000                 | No history of systemic immunotherapy                                     |
| Active CNS metastases excluded                                           | Skin Cancer     | Neurological        | 50%                           | Exclusion               | Observation         | SNOMED: 95891001                  | Brain MRI shows metastatic lesion                                        |
| Measurable disease per RECIST                                            | Skin Cancer     | Imaging             | 60%                           | Inclusion               | Observation         | SNOMED: 252416005                 | CT scan reveals 3 cm liver lesion                                        |
| BRAF V600 mutation status known                                          | Skin Cancer     | Genetic             | 50%                           | Inclusion               | Observation         | LOINC: 69548-6                    | BRAF V600E mutation detected by PCR                                      |
| Pregnancy or breastfeeding excluded                                      | Skin Cancer     | Reproductive        | 60%                           | Exclusion               | Observation         | SNOMED: 289908002                 | Patient currently breastfeeding                                          |
| Active autoimmune disease excluded                                       | Skin Cancer     | Autoimmune          | 50%                           | Exclusion               | Condition           | SNOMED: 64572001                  | History of rheumatoid arthritis                                          |
| ECOG performance status 0–1                                              | Skin Cancer     | Clinical            | 100%                          | Inclusion               | Observation         | LOINC: 89243-0                    | ECOG score recorded as 1                                                 |
| Uncontrolled cardiovascular disease excluded                             | Skin Cancer     | Cardiac             | 30%                           | Exclusion               | Condition           | SNOMED: 49601007                  | Severe heart failure within past 6 months                                |
| Adequate hematologic and organ function                                  | Skin Cancer     | Lab                 | 60%                           | Inclusion               | Observation         | SNOMED: 248234008                 | Liver and kidney panel within acceptable limits                          |
| Ocular melanoma excluded                                                 | Skin Cancer     | Diagnosis           | 50%                           | Exclusion               | Condition           | ICD-10: C69.9                     | Patient diagnosed with uveal melanoma                                    |
| Known HIV, HBV, or HCV excluded                                          | Skin Cancer     | Infection           | 50%                           | Exclusion               | Observation         | LOINC: 29771-3, 20416-4           | HIV screening positive                                                   |
| BRAF V600 mutation required                                              | Skin Cancer     | Genetic             | 40%                           | Inclusion               | Observation         | LOINC: 40861-5                    | BRAF V600E mutation detected by PCR                                      |
| Active brain metastases excluded                                         | Skin Cancer     | Imaging             | 40%                           | Exclusion               | Condition           | SNOMED: 94233001                  | MRI shows enhancing lesions consistent with CNS metastases               |
| Prior systemic therapy excluded                                          | Skin Cancer     | Treatment           | 30%                           | Exclusion               | Procedure           | SNOMED: 428341000000108           | Previously received ipilimumab                                           |
| Measurable disease required (RECIST)                                     | Skin Cancer     | Imaging             | 60%                           | Inclusion               | Observation         | SNOMED: 371531000000106           | CT shows measurable lymph node of 2.3 cm                                 |
| Excluded active autoimmune disease                                       | Skin Cancer     | Autoimmune          | 50%                           | Exclusion               | Condition           | SNOMED: 64572001                  | Diagnosed with systemic lupus erythematosus                              |
| Pregnancy or breastfeeding excluded                                      | Skin Cancer     | Reproductive        | 60%                           | Exclusion               | Observation         | SNOMED: 289908002                 | Patient is currently pregnant                                            |
| Prior BRAF/MEK inhibitors excluded                                       | Skin Cancer     | Treatment           | 30%                           | Exclusion               | Procedure           | RXNORM: 1373478                   | Patient previously treated with dabrafenib                               |
| Contraception requirement for participants                               | Skin Cancer     | Reproductive        | 60%                           | Inclusion               | Observation         | SNOMED: 386644000                 | Patient advised to use dual contraception methods                        |
| Excluded prior anti-PD-1/PD-L1/PD-L2 therapy                             | Skin Cancer     | Treatment           | 30%                           | Exclusion               | Procedure           | RXNORM: 1792776                   | Treated previously with nivolumab                                        |
| Hepatic/renal/lab function within limits                                 | Skin Cancer     | Clinical            | 50%                           | Inclusion               | Observation         | LOINC: 1975-2, 24323-8            | ALT, AST, bilirubin within normal limits                                 |
| History of ocular/retinal diseases excluded                              | Skin Cancer     | Ophthalmologic      | 30%                           | Exclusion               | Condition           | SNOMED: 386661006                 | Prior history of central serous retinopathy                              |
| Life expectancy ≥3 months                                                | Skin Cancer     | Clinical            | 20%                           | Inclusion               | Observation         | SNOMED: 277026009                 | Estimated life expectancy exceeds 3 months                               |
| ECOG performance status ≤ 1 or 2                                         | Blood Cancer    | Clinical            | 90%                           | Inclusion               | Observation         | LOINC: 89243-0                    | ECOG status recorded as 1                                                |
| Adequate organ function                                                  | Blood Cancer    | Clinical            | 70%                           | Inclusion               | Observation         | SNOMED: 248234008                 | Liver and renal panels within normal limits                              |
| Confirmed diagnosis via histology                                        | Blood Cancer    | Diagnosis           | 100%                          | Inclusion               | Condition           | ICD-10: varies                    | Diagnosis confirmed through pathology                                    |
| CNS involvement excluded                                                 | Blood Cancer    | Neurological        | 60%                           | Exclusion               | Condition           | SNOMED: 127013003                 | No evidence of CNS disease on MRI                                        |
| Active infection (e.g., HIV, HBV, HCV) excluded                          | Blood Cancer    | Infection           | 70%                           | Exclusion               | Observation         | LOINC: 29771-3, 20416-4           | Patient tested positive for Hepatitis B                                  |
| Prior anti-CD20 or CD38 therapy                                          | Blood Cancer    | Treatment           | 50%                           | Inclusion               | Procedure           | SNOMED: 429060002                 | Rituximab administered in prior treatment                                |
| Philadelphia chromosome negative                                         | Blood Cancer    | Genetic             | 20%                           | Inclusion               | Observation         | LOINC: 34572-6                    | BCR-ABL fusion not detected by FISH                                      |
| No prior systemic therapy                                                | Blood Cancer    | Treatment           | 30%                           | Inclusion               | Procedure           | SNOMED: 386053000                 | No chemotherapy history                                                  |
| Pregnancy or breastfeeding excluded                                      | Blood Cancer    | Reproductive        | 60%                           | Exclusion               | Observation         | SNOMED: 289908002                 | Patient is currently pregnant                                            |
| Measurable disease required                                              | Blood Cancer    | Imaging             | 50%                           | Inclusion               | Observation         | SNOMED: 252416005                 | CT shows measurable mass                                                 |
| Life expectancy ≥ 3 months                                               | Blood Cancer    | Clinical            | 50%                           | Inclusion               | Observation         | SNOMED: 277026009                 | Estimated survival time exceeds 3 months                                 |
| No prior allogeneic stem cell transplant                                 | Blood Cancer    | Treatment           | 40%                           | Exclusion               | Procedure           | SNOMED: 170838008                 | History reveals patient underwent allogeneic transplant                  |
| Platelet count ≥ 75,000/µL                                               | Blood Cancer    | Lab                 | 60%                           | Inclusion               | Observation         | LOINC: 26515-7                    | Platelet count was 120,000 per microliter at screening                   |
| Creatinine clearance ≥ 50 mL/min                                         | Blood Cancer    | Lab                 | 50%                           | Inclusion               | Observation         | LOINC: 2160-0                     | Creatinine clearance calculated at 52 mL/min                             |
| No uncontrolled hypertension                                             | Blood Cancer    | Clinical            | 40%                           | Exclusion               | Condition           | ICD-10: I10                       | Blood pressure well-controlled on current medications                    |
| HIV, HBV, or HCV excluded                                                | Blood Cancer    | Infection           | 50%                           | Exclusion               | Observation         | LOINC: 29771-3, 20416-4           | HIV test returned positive                                               |
| ECOG Performance Status 0–2                                              | Blood Cancer    | Clinical            | 60%                           | Inclusion               | Observation         | LOINC: 89243-0                    | ECOG score documented as 1                                               |
| Active CNS involvement excluded                                          | Blood Cancer    | Neurological        | 30%                           | Exclusion               | Condition           | SNOMED: 127013003                 | CSF cytology positive for blasts                                         |
| Platelet count ≥ 75,000/μL                                               | Blood Cancer    | Lab                 | 20%                           | Inclusion               | Observation         | LOINC: 26515-7                    | Platelet count recorded as 82,000/μL                                     |
| Creatinine clearance ≥ 50 mL/min                                         | Blood Cancer    | Lab                 | 30%                           | Inclusion               | Observation         | LOINC: 2160-0                     | Calculated CrCl = 62 mL/min using Cockcroft-Gault formula                |
| History of allogeneic stem cell transplant                               | Blood Cancer    | Treatment           | 20%                           | Exclusion               | Procedure           | SNOMED: 5960008                   | Underwent allo-SCT 2 years ago                                           |
| Prior CD19-directed therapy                                              | Blood Cancer    | Treatment           | 20%                           | Exclusion               | Procedure           | RXNORM: 1792770                   | Treated previously with CD19 CAR-T therapy                               |
| Measurable residual disease (MRD) ≥ 0.1%                                 | Blood Cancer    | Lab                 | 10%                           | Inclusion               | Observation         | LOINC: 77025-8                    | MRD detected at 0.3% via flow cytometry                                  |
| Active GVHD requiring systemic treatment                                 | Blood Cancer    | Immune              | 20%                           | Exclusion               | Condition           | SNOMED: 24079001                  | Receiving steroids for Grade II GVHD                                     |
| Uncontrolled infection                                                   | Blood Cancer    | Infection           | 30%                           | Exclusion               | Observation         | LOINC: 11488-4                    | Sepsis requiring broad-spectrum IV antibiotics                           |
| No uncontrolled hypertension                                             | Blood Cancer    | Cardiac             | 20%                           | Exclusion               | Observation         | SNOMED: 38341003                  | Blood pressure uncontrolled despite medication                           |
| LVEF ≥ 50%                                                               | Blood Cancer    | Cardiac             | 30%                           | Inclusion               | Observation         | LOINC: 33878-0                    | Echocardiogram shows LVEF of 55%                                         |
| Age ≥ 18 years                                                           | Blood Cancer    | Demographic         | 100%                          | Inclusion               | Patient             | SNOMED: 397669002                 | Patient is a 46-year-old male                                            |
| No prior anti-CD38 therapy                                               | Blood Cancer    | Treatment           | 10%                           | Exclusion               | Procedure           | RXNORM: 1792953                   | No history of daratumumab or similar therapy                             |
| Refractory or relapsed disease after ≥1 line of therapy                  | Blood Cancer    | Treatment           | 40%                           | Inclusion               | Condition           | SNOMED: 313229003                 | Relapsed multiple myeloma after bortezomib-based regimen                 |
| Total bilirubin ≤ 1.5x ULN                                               | Blood Cancer    | Lab                 | 40%                           | Inclusion               | Observation         | LOINC: 1975-2                     | Total bilirubin level recorded at 1.2x ULN                               |
| No known CNS involvement                                                 | Blood Cancer    | Neurological        | 40%                           | Exclusion               | Condition           | SNOMED: 127013003                 | No clinical or imaging evidence of CNS disease                           |
| No active graft-versus-host disease (GVHD)                               | Blood Cancer    | Immune              | 30%                           | Exclusion               | Condition           | SNOMED: 370197006                 | GVHD resolved, no active symptoms observed                               |
| Informed consent obtained                                                | Blood Cancer    | Administrative      | 100%                          | Inclusion               | Consent             | SNOMED: 394814009                 | Signed informed consent available in patient record                      |
| Not pregnant or breastfeeding                                            | Blood Cancer    | Reproductive        | 70%                           | Exclusion               | Observation         | SNOMED: 289908002                 | Patient denies pregnancy; negative pregnancy test                        |
| Creatinine clearance ≥ 60 mL/min                                         | Blood Cancer    | Lab                 | 40%                           | Inclusion               | Observation         | LOINC: 2160-0                     | eGFR calculated at 65 mL/min on lab report                               |
| No uncontrolled cardiovascular disease                                   | Blood Cancer    | Cardiac             | 30%                           | Exclusion               | Condition           | SNOMED: 49601007                  | Recent cardiac event ruled out; patient stable                           |
| Women of childbearing potential must use contraception                   | Blood Cancer    | Reproductive        | 50%                           | Inclusion               | Observation         | SNOMED: 386644000                 | Counseled on dual contraception before enrollment                        |
| Negative hepatitis B surface antigen                                     | Blood Cancer    | Infection           | 40%                           | Inclusion               | Observation         | LOINC: 5195-3                     | HBsAg test result was negative                                           |
| No investigational drug use within 28 days                               | Blood Cancer    | Treatment History   | 30%                           | Exclusion               | Procedure           | SNOMED: 430193006                 | Patient last enrolled in a trial >1 month ago                            |
| No uncontrolled active infection                                         | Blood Cancer    | Infection           | 40%                           | Exclusion               | Condition           | SNOMED: 87628006                  | Patient afebrile, blood cultures negative — no active infection          |
| Serum bilirubin ≤ 1.5 × ULN                                              | Blood Cancer    | Lab                 | 30%                           | Inclusion               | Observation         | LOINC: 1975-2                     | Total bilirubin recorded as 1.2 mg/dL                                    |
| Platelet count ≥ 75,000/μL                                               | Blood Cancer    | Lab                 | 40%                           | Inclusion               | Observation         | LOINC: 777-3                      | CBC shows platelets at 95,000/μL                                         |
| No prior CAR-T therapy                                                   | Blood Cancer    | Treatment History   | 30%                           | Exclusion               | Procedure           | SNOMED: 47301000000107            | No record of chimeric antigen receptor T-cell therapy                    |
| Life expectancy ≥ 12 weeks                                               | Blood Cancer    | Clinical            | 30%                           | Inclusion               | Observation         | SNOMED: 277026009                 | Oncologist estimates patient life expectancy exceeds 3 months            |
| Creatinine clearance ≥ 50 mL/min                                         | Blood Cancer    | Lab                 | 40%                           | Inclusion               | Observation         | LOINC: 2160-0                     | Creatinine clearance measured at 68 mL/min                               |
| No uncontrolled cardiovascular disease                                   | Blood Cancer    | Cardiac             | 30%                           | Exclusion               | Condition           | SNOMED: 418304008                 | Patient has stable angina, no recent cardiac events                      |
| Left ventricular ejection fraction ≥ 50%                                 | Blood Cancer    | Cardiac             | 30%                           | Inclusion               | Observation         | LOINC: 33878-0                    | Echocardiogram shows LVEF of 55%                                         |
| No prior allogeneic stem cell transplant                                 | Blood Cancer    | Treatment History   | 30%                           | Exclusion               | Procedure           | SNOMED: 397215005                 | No history of allogeneic HSCT in oncology record                         |
| Hepatitis B surface antigen negative                                     | Blood Cancer    | Infection           | 30%                           | Inclusion               | Observation         | LOINC: 5195-3                     | HBsAg test returned negative                                             |
| Absolute neutrophil count ≥ 1.0 × 10⁹/L                                  | Blood Cancer    | Lab                 | 40%                           | Inclusion               | Observation         | LOINC: 26499-4                    | ANC measured at 1.3 × 10⁹/L on CBC                                       |
| No CNS involvement by malignancy                                         | Blood Cancer    | Neurological        | 40%                           | Exclusion               | Condition           | SNOMED: 128613002                 | CSF negative for malignant cells                                         |
| Platelet count ≥ 75 × 10⁹/L                                              | Blood Cancer    | Lab                 | 40%                           | Inclusion               | Observation         | LOINC: 26515-7                    | Platelet count was 88 × 10⁹/L                                            |
| Hemoglobin ≥ 8.0 g/dL                                                    | Blood Cancer    | Lab                 | 40%                           | Inclusion               | Observation         | LOINC: 718-7                      | Hemoglobin measured at 9.2 g/dL                                          |
| Active GVHD requiring systemic therapy excluded                          | Blood Cancer    | Immune/Transplant   | 30%                           | Exclusion               | Condition           | SNOMED: 236423003                 | GVHD grade II managed with systemic corticosteroids                      |
